TW202328180A - 包含pd-1及tgf-brii結合域之多特異性結合部分 - Google Patents

包含pd-1及tgf-brii結合域之多特異性結合部分 Download PDF

Info

Publication number
TW202328180A
TW202328180A TW111144080A TW111144080A TW202328180A TW 202328180 A TW202328180 A TW 202328180A TW 111144080 A TW111144080 A TW 111144080A TW 111144080 A TW111144080 A TW 111144080A TW 202328180 A TW202328180 A TW 202328180A
Authority
TW
Taiwan
Prior art keywords
seq
heavy chain
tgf
amino acid
acid sequence
Prior art date
Application number
TW111144080A
Other languages
English (en)
Chinese (zh)
Inventor
塞西莉亞 安娜 威廉明娜 桂珍
派翠克 梅斯
肖恩 M 斯圖爾特
王亮權
Original Assignee
荷蘭商美勒斯公司
美商英塞特公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 荷蘭商美勒斯公司, 美商英塞特公司 filed Critical 荷蘭商美勒斯公司
Publication of TW202328180A publication Critical patent/TW202328180A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW111144080A 2021-11-19 2022-11-18 包含pd-1及tgf-brii結合域之多特異性結合部分 TW202328180A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2029844 2021-11-19
NL2029844 2021-11-19

Publications (1)

Publication Number Publication Date
TW202328180A true TW202328180A (zh) 2023-07-16

Family

ID=80625531

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111144080A TW202328180A (zh) 2021-11-19 2022-11-18 包含pd-1及tgf-brii結合域之多特異性結合部分

Country Status (18)

Country Link
US (1) US20230159645A1 (cg-RX-API-DMAC7.html)
EP (1) EP4433505A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542879A (cg-RX-API-DMAC7.html)
KR (1) KR20240101664A9 (cg-RX-API-DMAC7.html)
CN (2) CN119613560A (cg-RX-API-DMAC7.html)
AR (1) AR127714A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022389596A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231649A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001410A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024006325A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240201A (cg-RX-API-DMAC7.html)
EC (1) ECSP24039278A (cg-RX-API-DMAC7.html)
IL (1) IL312214A (cg-RX-API-DMAC7.html)
MX (1) MX2024006018A (cg-RX-API-DMAC7.html)
PE (1) PE20241477A1 (cg-RX-API-DMAC7.html)
TW (1) TW202328180A (cg-RX-API-DMAC7.html)
UY (1) UY40028A (cg-RX-API-DMAC7.html)
WO (1) WO2023089083A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121152809A (zh) * 2023-04-14 2025-12-16 因赛特公司 抗TGFβR2/PD-1双特异性抗体治疗癌症的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
CN110198738A (zh) * 2017-01-07 2019-09-03 默克专利有限公司 用于靶向的TGF-β抑制的给药方案和剂型
TWI917306B (zh) * 2017-07-06 2026-03-11 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的結合分子
TWI887193B (zh) * 2017-07-06 2025-06-21 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
CN116199780A (zh) * 2019-12-24 2023-06-02 美勒斯公司 TGF-β-RII结合蛋白质
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业(上海)股份有限公司 四价双特异性抗体、其制备方法和用途
WO2022099090A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. Heterodimeric antibodies that bind tgfbrii

Also Published As

Publication number Publication date
AU2022389596A1 (en) 2024-05-30
ECSP24039278A (es) 2024-07-31
PE20241477A1 (es) 2024-07-17
CL2024001410A1 (es) 2024-08-30
MX2024006018A (es) 2024-07-29
CN119613560A (zh) 2025-03-14
AR127714A1 (es) 2024-02-21
JP2024542879A (ja) 2024-11-18
US20230159645A1 (en) 2023-05-25
CA3231649A1 (en) 2023-05-25
IL312214A (en) 2024-06-01
KR20240101664A9 (ko) 2025-12-10
CN118265725A (zh) 2024-06-28
EP4433505A1 (en) 2024-09-25
KR20240101664A (ko) 2024-07-02
CR20240201A (es) 2024-07-15
WO2023089083A1 (en) 2023-05-25
CO2024006325A2 (es) 2024-06-27
UY40028A (es) 2023-05-31

Similar Documents

Publication Publication Date Title
JP2021184749A (ja) 融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
US20210315933A1 (en) Compositions and methods for tcr reprogramming using target specific fusion proteins
JP2020202867A (ja) キメラ受容体及びその使用方法
JP7022067B2 (ja) Foxp3由来のペプチドに特異的なt細胞受容体様抗体
JP2022501428A (ja) 抗lilrb2抗体およびその使用の方法
JP2024149487A (ja) ホスファターゼ動員による受容体の阻害
TW201741337A (zh) CD40L-Fc融合多肽及其使用方法
CN107835820A (zh) 识别癌症特异性IL13Rα2的CAR T细胞
JP2006528626A (ja) Nk細胞増強化合物を使用する治療抗体の有効性を増大させる方法および組成物
TW202216745A (zh) 包含經修飾il-2多肽之多肽及其用途
CN115989033B (zh) 用于使用cd70特异性融合蛋白进行tcr重编程的组合物和方法
JP2022500484A (ja) 抗ヒトvsig4抗体およびその使用
JP2023519644A (ja) Ssea-4結合メンバー
CN118715242A (zh) 包含b7-h3结合多肽的组合物和方法
KR20230008144A (ko) Cd19를 표적화하는 키메라 항원 수용체 및 그의 용도
US20210355220A1 (en) Antibodies specific to ctla-4 and uses thereof
US20230159645A1 (en) Multispecific binding moieties comprising pd-1 and tgf-brii binding domains
TW202506711A (zh) 切換受體
HK40129273A (en) Switch receptors
TW202019475A (zh) Cd137結合分子